No Data
Express News | Cabaletta Bio Inc : Jefferies Cuts Target Price to $28 From $31
Maintaining Buy Recommendation on Cabaletta Bio Amid Overestimated Trial Risks
Cabaletta Bio: A Buy Recommendation Despite Safety Incident, With Anticipated Future Growth in Autoimmune CAR-T
William Blair Sticks to Its Buy Rating for Cabaletta Bio (CABA)
Cabaletta Bio Unveils Updated Corporate Strategy Details
Express News | Cabaletta Bio Shares Are Trading Lower. The Company Reported Q2 Financial Results
diamonds : Excuse me, can shares held still be valid after ENDPQ's restructuring?